Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 2Lymphoma, Non-Hodgkin 1Lymphoma, B-Cell 1Lymphoma 1Hematologic Diseases 1

Interventions

Rituximab 6Lenalidomide 3Bendamustine Hydrochloride 3pirtobrutinib 2Cyclophosphamide 2venetoclax 1umbralisib 1ublituximab 1tocilizumab 1obinutuzumab 1idelalisib 1glofitamab 1fludarabine 1atezolizumab 1acalabrutinib 1Vincristine 1Standard of Care 1Prednisone 1Doxorubicin 1Brentuximab Vedotin 1Appointments and Schedules 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has announcements × Lymphoma, Non-Hodgkin × idelalisib × Clear all
NCT04666038 2026-04-24

BRUIN CLL-321

Eli Lilly and Company

Phase 3 Active not recruiting
238 enrolled 17 charts 1 FDA
LymphoidOther hematologic neoplasm

Hematologic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡